Misrepresenting harms in antidepressant trials- more evidence from Clinical Study Reports.

Joanna Moncrieff,
Senior Lecturer,
Division of psychiatry,
University College London,
Maple House,
149 Tottenham Court Road,
London,
W1T 7NF.

E mail address: j.moncrieff@ucl.ac.uk

Word count: 737
Misrepresenting harms in antidepressant trials- more evidence from Clinical Study Reports.

People in the United Kingdom are consuming more than four times as many antidepressants as they were two decades ago (1). Despite this, we still do not fully understand the effects of these drugs, nor can we be confident about their risk-benefit ratio.

Unresolved issues include the nature and frequency of potential serious adverse effects such as self-harming or suicidal actions, suicidal ideation and aggression. In the linked paper, Sharma et al use Clinical Study Reports (CSRs) to explore these adverse effects. CSRs are prepared by pharmaceutical companies for the purpose of obtaining marketing authorisation. There are guidelines about contents and presentation of CSR’s (2) but no mandatory requirements. Consequently, although CSRs usually contain more data than published articles (3), the level of detail varies. Moreover, there may be differences between what is reported in the body of the CSR and data contained in appendices, such as individual patient listings of adverse events or narratives of serious adverse events.

Sharma et al’s analysis of CSRs reveals misrepresentation of adverse events. Comparing the ‘results’ reported in CSRs with data from individual patient listings or patient narratives revealed misclassification of deaths on antidepressants, and misrepresentation of suicidal events. More than half of the suicide attempts and instances of suicidal ideation were coded as ‘emotional lability’ or ‘worsening of depression,’ for example. Summary reports published on Eli Lilly’s website were found to be even more incomplete, listing only 10% of the suicide attempts revealed in the corresponding CSRs, and no instances of suicidal ideation.

Over half of the CSRs selected by Sharma et al had no individual patient listings, this data having been withheld. This begs the question of how many more adverse events would have been revealed if individual patient listings were available for all trials, and raises concerns about why this information is allowed to be withheld.

The current review is consistent with other evidence pointing to an increase in suicidal behaviour and ideation among children and adolescents taking selective serotonin reuptake inhibitors (SSRIs) (4). The paper by Sharma et al is the first large-scale, quantitative analysis to demonstrate an increase in aggressive behaviour in this age group. The analysis did not detect an increase in suicide, suicide attempts, suicidal ideation or aggression in adults and meta-analyses of data on adults remains conflicting (5; 6). Early case reports, published
before the issue became controversial, document occurrence of these effects in adults, however, and also provide evidence as to the mechanism of these effects. These reports describe a state of agitation, somewhat similar to the akathisia produced by antipsychotics, associated with intense and violent suicidal preoccupation (7). However, as Sharma et al demonstrate, recording of ‘akathisia’ in antidepressant trials remains inconsistent and unreliable, hence we have little idea of the frequency of this effect.

Although ‘activation’ effects (or akathisia) are recognized, there is little acknowledgement that antidepressants have mind-altering properties that are independent of their supposed effects on underlying mental disorders. One study revealed various changes to emotions and behaviour in patients taking antidepressants, which were associated with suicidal ideation (8). Evidence suggests there can be severe and sometimes prolonged withdrawal syndromes (9). With some exceptions (10), however, we lack the detailed exploration through animal behaviour and healthy volunteer studies that might clarify the range, nature and duration of the alterations that antidepressants induce.

Despite their widespread use, antidepressants are only modestly more effective than placebo in trials of depression. Measures of global clinical improvement suggest the difference is not clinically relevant or even detectable (11). Moreover, placebo-controlled studies do not distinguish whether the effects of a drug are attributable to the targeting of putative underlying mechanisms, or a consequence of the drug’s mind-altering effects. The blunting of emotions produced by SSRIs may directly affect depression rating scale scores, for example, and their psychoactive and physical effects may influence patient expectations, promoting an amplified placebo effect (12).

With doubts about the efficacy and effectiveness of antidepressants, and evidence that they can produce such serious adverse reactions as suicidal and aggressive tendencies, regulators and the public need access to more comprehensive and reliable data. The results reported in CSRs, on which decisions about market authorization are based, are likely to underestimate the extent of drug-related harms. We need access to original data from trials, but we also need more research that addresses the whole range of antidepressant-induced behavioural, emotional and physical alterations with acute treatment, long-term use and following withdrawal.
Acknowledgements: the author would like to thank Luke Montagu and Millie Kieve for their comments on this editorial.

Competing interest statement:
I have read and understood the BMJ Group policy on declaration of interests and declare the following interests: I have no competing financial interests. I am co-chair person of the Critical Psychiatry Network.

Copyright statement:
The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

Reference List


